APA (7th ed.) Citation

JJL, v. G., J, B., SG, E., AWJM, G., EFJ, d. V., GAP, H., . . . CP, S. (2022). Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(31), 3642. https://doi.org/10.1200/JCO.22.00400

Chicago Style (17th ed.) Citation

JJL, van Geel, et al. "Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 40, no. 31 (2022): 3642. https://doi.org/10.1200/JCO.22.00400.

MLA (9th ed.) Citation

JJL, van Geel, et al. "Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 40, no. 31, 2022, p. 3642, https://doi.org/10.1200/JCO.22.00400.